Retrospective cohort study of biomarker-directed therapy in Black and White men with metastatic castration-resistant prostate cancer

Black men have higher incidence and mortality from prostate cancer than White men. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is not known. A retrospective cohort study of 962 men with mCRPC found that mismatch repair deficiency or microsatellite instability-high was significantly more frequent in Black men than White men, while PTEN alterations en TMPRSS alterations were less frequent in Black than in White men. Black men were significantly less likely to receive matched targeted therapy than White men. There were no differences between the two cohorts in response to targeted therapy or survival.